Egr-1 mediates low-dose arecoline induced human oral mucosa fibroblast proliferation via transactivation of Wnt5a expression.

Qiang ChenJiuyang JiaoYouyuan WangZhihui MaiJing RenSijie HeXiaolan LiZheng Chen

Published in: BMC molecular and cell biology (2020)

Egr-1 mediates the effect of low dose arecoline treatment on human oral mucosa fibroblast proliferation by transactivating the expression of Wnt5a. Therefore, Egr inhibitors and Wnt5a antibodies are potential therapies for treatment of oral submucosal fibrosis and oral cancer.

Keyphrases

low dose
endothelial cells
stem cells
cell proliferation
poor prognosis
high dose
signaling pathway
induced pluripotent stem cells
binding protein
risk assessment
smoking cessation